MX2017015666A - Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). - Google Patents
Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla).Info
- Publication number
- MX2017015666A MX2017015666A MX2017015666A MX2017015666A MX2017015666A MX 2017015666 A MX2017015666 A MX 2017015666A MX 2017015666 A MX2017015666 A MX 2017015666A MX 2017015666 A MX2017015666 A MX 2017015666A MX 2017015666 A MX2017015666 A MX 2017015666A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide presented
- membrane protein
- cell receptor
- latent membrane
- human hla
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 102000018697 Membrane Proteins Human genes 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 abstract 2
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173330P | 2015-06-09 | 2015-06-09 | |
| PCT/US2016/036735 WO2016201124A2 (en) | 2015-06-09 | 2016-06-09 | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015666A true MX2017015666A (es) | 2018-07-06 |
Family
ID=57504187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015666A MX2017015666A (es) | 2015-06-09 | 2016-06-09 | Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501559B2 (enExample) |
| EP (1) | EP3307319A4 (enExample) |
| JP (2) | JP7000162B2 (enExample) |
| KR (1) | KR20180023949A (enExample) |
| CN (1) | CN108289950B (enExample) |
| AU (1) | AU2016274767B2 (enExample) |
| CA (1) | CA2988768A1 (enExample) |
| HK (1) | HK1252653A1 (enExample) |
| IL (2) | IL281396B (enExample) |
| MX (1) | MX2017015666A (enExample) |
| SG (1) | SG10202110887PA (enExample) |
| WO (1) | WO2016201124A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| CA2988768A1 (en) | 2015-06-09 | 2016-12-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| RU2767209C2 (ru) | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| BR112019011277A2 (pt) | 2016-12-02 | 2019-10-22 | University Of Southern California | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. |
| IL310182A (en) | 2017-04-26 | 2024-03-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures of chimeric antibody/T-cell receptor and uses thereof |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| CA3091143A1 (en) | 2018-02-15 | 2019-08-22 | Memorial Sloan-Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| CN112189018A (zh) | 2018-04-20 | 2021-01-05 | 汉诺威医学院 | 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞 |
| CN113423724B (zh) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | Ebv表位高亲和力t细胞受体 |
| US12084500B2 (en) * | 2019-01-23 | 2024-09-10 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| WO2020160189A1 (en) * | 2019-01-29 | 2020-08-06 | Gritstone Oncology, Inc. | Multispecific binding proteins |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| WO2020191365A1 (en) * | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| MX2022000081A (es) * | 2019-07-03 | 2022-04-27 | Regeneron Pharma | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso. |
| EP3786178A1 (en) * | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| CN111690617B (zh) * | 2020-05-18 | 2023-05-02 | 李欣 | 抗eb病毒lmp2a的单克隆抗体及其细胞株和应用 |
| CN114457165A (zh) * | 2022-04-13 | 2022-05-10 | 深圳荻硕贝肯精准医学有限公司 | 一种用于检测hla-a02基因的引物探针组、试剂盒及检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1998034957A1 (en) | 1997-02-11 | 1998-08-13 | Immunomedics, Inc. | STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| AU783502B2 (en) | 1999-11-24 | 2005-11-03 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | PROCESS FOR PURIFYING ANTIBODY |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011062560A1 (en) | 2009-11-19 | 2011-05-26 | National University Of Singapore | Method for producing t cell receptor-like monoclonal antibodies and uses thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG10201602159VA (en) | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| DK3030581T3 (da) * | 2013-08-07 | 2021-04-12 | Affimed Gmbh | Antistofbindingssteder, der er specifikke for egfrviii |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| WO2015199618A1 (en) | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| CA2988768A1 (en) | 2015-06-09 | 2016-12-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
-
2016
- 2016-06-09 CA CA2988768A patent/CA2988768A1/en active Pending
- 2016-06-09 AU AU2016274767A patent/AU2016274767B2/en not_active Ceased
- 2016-06-09 HK HK18111960.3A patent/HK1252653A1/zh unknown
- 2016-06-09 IL IL281396A patent/IL281396B/en unknown
- 2016-06-09 SG SG10202110887PA patent/SG10202110887PA/en unknown
- 2016-06-09 MX MX2017015666A patent/MX2017015666A/es unknown
- 2016-06-09 US US15/735,133 patent/US10501559B2/en active Active
- 2016-06-09 KR KR1020187000659A patent/KR20180023949A/ko not_active Ceased
- 2016-06-09 WO PCT/US2016/036735 patent/WO2016201124A2/en not_active Ceased
- 2016-06-09 CN CN201680046924.2A patent/CN108289950B/zh not_active Expired - Fee Related
- 2016-06-09 JP JP2017564407A patent/JP7000162B2/ja not_active Expired - Fee Related
- 2016-06-09 EP EP16808304.6A patent/EP3307319A4/en not_active Withdrawn
-
2017
- 2017-11-30 IL IL256035A patent/IL256035A/en unknown
-
2019
- 2019-10-28 US US16/665,708 patent/US11168150B2/en active Active
-
2021
- 2021-05-06 JP JP2021078441A patent/JP2021106623A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20180258187A1 (en) | 2018-09-13 |
| CN108289950A (zh) | 2018-07-17 |
| IL281396B (en) | 2022-07-01 |
| US10501559B2 (en) | 2019-12-10 |
| HK1252653A1 (zh) | 2019-05-31 |
| CN108289950B (zh) | 2022-10-21 |
| AU2016274767B2 (en) | 2022-05-19 |
| AU2016274767A1 (en) | 2018-01-04 |
| US11168150B2 (en) | 2021-11-09 |
| KR20180023949A (ko) | 2018-03-07 |
| JP2018520667A (ja) | 2018-08-02 |
| JP7000162B2 (ja) | 2022-02-10 |
| US20200115470A1 (en) | 2020-04-16 |
| IL281396A (en) | 2021-04-29 |
| EP3307319A2 (en) | 2018-04-18 |
| SG10202110887PA (en) | 2021-11-29 |
| JP2021106623A (ja) | 2021-07-29 |
| EP3307319A4 (en) | 2019-05-22 |
| CA2988768A1 (en) | 2016-12-15 |
| WO2016201124A3 (en) | 2017-03-30 |
| WO2016201124A2 (en) | 2016-12-15 |
| IL256035A (en) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017015666A (es) | Agentes de anticuerpos similares al receptor de celulas t, especificos para peptidos de proteina latente de membrana 2a del virus de epstein-barr (ebv) presentado por antigeno leucocitario humano (hla). | |
| PH12019502763A1 (en) | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| MX2017004007A (es) | Modulacion de celulas mieloides estimulantes y no estimulantes. | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| PH12018500663A1 (en) | Antigen-binding proteins that activate the leptin receptor | |
| PH12018500664B1 (en) | Anti-lag3 antibodies and uses thereof | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
| MX2010006767A (es) | Anticuerpos de virus de hepatitis c. | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| MA40527A (fr) | Protéines de liaison à l'antigène se liant à wisp5 | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| MX2015016978A (es) | Proteinas de union a antigeno neutralizantes de citomegalovirus. | |
| PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| PH12016501444A1 (en) | Antibodies against f glycoprotein of hendra and nipah viruses | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2016075546A3 (en) | Antibodies that neutralize ebola virus and uses thereof | |
| MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
| PH12022550671A1 (en) | Antigen binding proteins |